SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Revance Therapeutics, Inc. – ‘10-Q’ for 9/30/20 – ‘EX-101.SCH’

On:  Monday, 11/9/20, at 4:46pm ET   ·   For:  9/30/20   ·   Accession #:  1479290-20-105   ·   File #:  1-36297

Previous ‘10-Q’:  ‘10-Q’ on 8/6/20 for 6/30/20   ·   Next:  ‘10-Q’ on 5/10/21 for 3/31/21   ·   Latest:  ‘10-Q’ on 5/9/24 for 3/31/24   ·   15 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

11/09/20  Revance Therapeutics, Inc.        10-Q        9/30/20   83:8.3M

Quarterly Report   —   Form 10-Q
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML   1.17M 
 2: EX-10.1     Material Contract                                   HTML     45K 
 3: EX-10.2     Material Contract                                   HTML    129K 
 4: EX-10.5     Material Contract                                   HTML     35K 
 5: EX-31.1     Certification -- §302 - SOA'02                      HTML     27K 
 6: EX-31.2     Certification -- §302 - SOA'02                      HTML     27K 
 7: EX-32.1     Certification -- §906 - SOA'02                      HTML     25K 
 8: EX-32.2     Certification -- §906 - SOA'02                      HTML     25K 
15: R1          Cover                                               HTML     75K 
16: R2          Condensed Consolidated Balance Sheets               HTML    118K 
17: R3          Condensed Consolidated Balance Sheets               HTML     40K 
                (Parenthetical)                                                  
18: R4          Condensed Consolidated Statement of Operations and  HTML     91K 
                Comprehensive Loss                                               
19: R5          Condensed Consolidated Statements of Shareholders'  HTML    113K 
                Equity                                                           
20: R6          Condensed Consolidated Statements of Shareholders'  HTML     25K 
                Equity (Parenthetical)                                           
21: R7          Condensed Consolidated Statements of Cash Flows     HTML    125K 
22: R8          The Company and Summary of Significant Accounting   HTML     56K 
                Policies                                                         
23: R9          Revenue                                             HTML     57K 
24: R10         Business Combination                                HTML     67K 
25: R11         Cash Equivalents and Short-Term Investments         HTML     57K 
26: R12         Filler Distribution Agreement                       HTML     50K 
27: R13         Intangible Assets                                   HTML     50K 
28: R14         Inventories                                         HTML     24K 
29: R15         Accruals and Other Current Liabilities              HTML     35K 
30: R16         Derivative Liability                                HTML     26K 
31: R17         Leases                                              HTML     49K 
32: R18         Convertible Senior Notes                            HTML     47K 
33: R19         Stockholders' Equity and Stock-based Compensation   HTML     51K 
34: R20         Fair Value Measurements                             HTML     72K 
35: R21         Commitments and Contingencies                       HTML     32K 
36: R22         Segment Information                                 HTML     57K 
37: R23         The Company and Summary of Significant Accounting   HTML     72K 
                Policies (Policies)                                              
38: R24         Revenue (Tables)                                    HTML     45K 
39: R25         Business Combination (Tables)                       HTML     66K 
40: R26         Cash Equivalents and Short-term Investments         HTML     55K 
                (Tables)                                                         
41: R27         Intangible Assets (Tables)                          HTML     65K 
42: R28         Accruals and Other Current Liabilities (Tables)     HTML     34K 
43: R29         Leases (Tables)                                     HTML     51K 
44: R30         Convertible Senior Notes (Tables)                   HTML     36K 
45: R31         Stockholders' Equity and Stock-based Compensation   HTML     46K 
                (Tables)                                                         
46: R32         Fair Value Measurements (Tables)                    HTML     72K 
47: R33         Segment Information (Tables)                        HTML     52K 
48: R34         The Company and Summary of Significant Accounting   HTML     50K 
                Policies- Additional Information (Detail)                        
49: R35         Revenue -Revenues Disaggregated by Timing of        HTML     49K 
                Transfer of Goods or Services (Details)                          
50: R36         Revenue (Details)                                   HTML     60K 
51: R37         Business Combination - Narrative (Details)          HTML     51K 
52: R38         Business Combination - Consideration Transferred    HTML     41K 
                (Details)                                                        
53: R39         Business Combination - Fair Value of Assets         HTML     55K 
                Acquired and Liabilities Assumed (Details)                       
54: R40         Business Combination - Intangible Assets Acquired   HTML     42K 
                (Details)                                                        
55: R41         Business Combination - Pro Forma Financial          HTML     29K 
                Information (Details)                                            
56: R42         Cash Equivalents and Short-term Investments         HTML     56K 
                (Detail)                                                         
57: R43         Filler Distribution Agreement - Narrative           HTML     40K 
                (Details)                                                        
58: R44         Intangible Assets - Intangible Assets and the       HTML     51K 
                Remaining Useful Lives (Details)                                 
59: R45         Intangible Assets - Narrative (Details)             HTML     26K 
60: R46         Intangible Assets - Expected Amortization Expense   HTML     38K 
                for the Unamortized Acquired Intangible Assets                   
                (Details)                                                        
61: R47         Inventories (Details)                               HTML     25K 
62: R48         Accruals and Other Current Liabilities (Details)    HTML     38K 
63: R49         Derivative Liability - Additional Information       HTML     41K 
                (Detail)                                                         
64: R50         Leases (Details)                                    HTML     28K 
65: R51         Leases - Operating Lease Costs (Details)            HTML     30K 
66: R52         Leases - Operating Lease Liability Maturities       HTML     44K 
                (Details)                                                        
67: R53         Leases - Supplemental Cash Flow Information         HTML     27K 
                (Details)                                                        
68: R54         Convertible Senior Notes (Details)                  HTML     67K 
69: R55         Convertible Senior Notes - Interest Expense         HTML     45K 
                (Details)                                                        
70: R56         Convertible Senior Notes - Carrying Amount of       HTML     33K 
                Liability Component (Details)                                    
71: R57         Convertible Senior Notes - Capped Call              HTML     36K 
                Transactions (Details)                                           
72: R58         Stockholders' Equity and Stock-based Compensation   HTML     92K 
                - Stock Option Plan Additional Information                       
                (Details)                                                        
73: R59         Stockholders' Equity and Stock-based Compensation   HTML     38K 
                - Common Stock Equivalents Excluded from the                     
                Calculation of Earnings per Share (Details)                      
74: R60         Stockholders' Equity and Stock-based Compensation   HTML     31K 
                - Stock Option Plan Schedule of Stock-based                      
                Compensation Expense (Details)                                   
75: R61         Fair Value Measurements - Schedule of Fair Value    HTML     72K 
                of Financial Instruments (Detail)                                
76: R62         Fair Value Measurements - Summary of Changes in     HTML     32K 
                Fair Value of Financial Instruments (Detail)                     
77: R63         Commitments and Contingencies - Additional          HTML     43K 
                Information (Detail)                                             
78: R64         Segment Information - Reconciliation of Segment     HTML     37K 
                Revenue to Consolidated Revenue (Details)                        
79: R65         Segment Information - Reconciliation of Segment     HTML     34K 
                Loss from Operations to Consolidated Loss from                   
                Operations (Details)                                             
81: XML         IDEA XML File -- Filing Summary                      XML    145K 
14: XML         XBRL Instance -- rvnc-20200930_htm                   XML   1.86M 
80: EXCEL       IDEA Workbook of Financial Reports                  XLSX    104K 
10: EX-101.CAL  XBRL Calculations -- rvnc-20200930_cal               XML    251K 
11: EX-101.DEF  XBRL Definitions -- rvnc-20200930_def                XML    654K 
12: EX-101.LAB  XBRL Labels -- rvnc-20200930_lab                     XML   1.50M 
13: EX-101.PRE  XBRL Presentations -- rvnc-20200930_pre              XML    928K 
 9: EX-101.SCH  XBRL Schema -- rvnc-20200930                         XSD    153K 
82: JSON        XBRL Instance as JSON Data -- MetaLinks              359±   538K 
83: ZIP         XBRL Zipped Folder -- 0001479290-20-000105-xbrl      Zip    405K

‘EX-101.SCH’   —   XBRL Schema — rvnc-20200930

This Exhibit is an XBRL XML File.

                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<!-- XBRL Document Created with Wdesk from Workiva -->
<!-- Copyright 2020 Workiva -->
<!-- r:f0dd895a-70c8-43fb-ae88-a8c7f4e8c034,g:5489a588-bc01-4c33-a1a2-f42bbc77e06d -->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:rvnc="http://www.revance.com/20200930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.revance.com/20200930">
<xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
<xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
<xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
<xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
<xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
<xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
<xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
<xs:annotation>
<xs:appinfo>
<link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rvnc-20200930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rvnc-20200930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rvnc-20200930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rvnc-20200930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
<link:roleType id="Cover" roleURI="http://www.revance.com/role/Cover">
<link:definition> 0001001 - Document - Cover </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.revance.com/role/CondensedConsolidatedBalanceSheets">
<link:definition> 1001002 - Statement - Condensed Consolidated Balance Sheets </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.revance.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
<link:definition> 1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="CondensedConsolidatedStatementofOperationsandComprehensiveLoss" roleURI="http://www.revance.com/role/CondensedConsolidatedStatementofOperationsandComprehensiveLoss">
<link:definition> 1003004 - Statement - Condensed Consolidated Statement of Operations and Comprehensive Loss </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="CondensedConsolidatedStatementsofShareholdersEquity" roleURI="http://www.revance.com/role/CondensedConsolidatedStatementsofShareholdersEquity">
<link:definition> 1004005 - Statement - Condensed Consolidated Statements of Shareholders' Equity </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="CondensedConsolidatedStatementsofShareholdersEquityParenthetical" roleURI="http://www.revance.com/role/CondensedConsolidatedStatementsofShareholdersEquityParenthetical">
<link:definition> 1005006 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Parenthetical) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.revance.com/role/CondensedConsolidatedStatementsofCashFlows">
<link:definition> 1006007 - Statement - Condensed Consolidated Statements of Cash Flows </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="TheCompanyandSummaryofSignificantAccountingPolicies" roleURI="http://www.revance.com/role/TheCompanyandSummaryofSignificantAccountingPolicies">
<link:definition> 2101101 - Disclosure - The Company and Summary of Significant Accounting Policies </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="TheCompanyandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.revance.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesPolicies">
<link:definition> 2202201 - Disclosure - The Company and Summary of Significant Accounting Policies (Policies) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="TheCompanyandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.revance.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail">
<link:definition> 2403401 - Disclosure - The Company and Summary of Significant Accounting Policies- Additional Information (Detail) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="Revenue" roleURI="http://www.revance.com/role/Revenue">
<link:definition> 2104102 - Disclosure - Revenue </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="RevenueTables" roleURI="http://www.revance.com/role/RevenueTables">
<link:definition> 2305301 - Disclosure - Revenue (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="RevenueRevenuesDisaggregatedbyTimingofTransferofGoodsorServicesDetails" roleURI="http://www.revance.com/role/RevenueRevenuesDisaggregatedbyTimingofTransferofGoodsorServicesDetails">
<link:definition> 2406402 - Disclosure - Revenue -Revenues Disaggregated by Timing of Transfer of Goods or Services (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="RevenueDetails" roleURI="http://www.revance.com/role/RevenueDetails">
<link:definition> 2407403 - Disclosure - Revenue (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="BusinessCombination" roleURI="http://www.revance.com/role/BusinessCombination">
<link:definition> 2108103 - Disclosure - Business Combination </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="BusinessCombinationTables" roleURI="http://www.revance.com/role/BusinessCombinationTables">
<link:definition> 2309302 - Disclosure - Business Combination (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="BusinessCombinationNarrativeDetails" roleURI="http://www.revance.com/role/BusinessCombinationNarrativeDetails">
<link:definition> 2410404 - Disclosure - Business Combination - Narrative (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="BusinessCombinationConsiderationTransferredDetails" roleURI="http://www.revance.com/role/BusinessCombinationConsiderationTransferredDetails">
<link:definition> 2411405 - Disclosure - Business Combination - Consideration Transferred (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="BusinessCombinationFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://www.revance.com/role/BusinessCombinationFairValueofAssetsAcquiredandLiabilitiesAssumedDetails">
<link:definition> 2412406 - Disclosure - Business Combination - Fair Value of Assets Acquired and Liabilities Assumed (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="BusinessCombinationIntangibleAssetsAcquiredDetails" roleURI="http://www.revance.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails">
<link:definition> 2413407 - Disclosure - Business Combination - Intangible Assets Acquired (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="BusinessCombinationProFormaFinancialInformationDetails" roleURI="http://www.revance.com/role/BusinessCombinationProFormaFinancialInformationDetails">
<link:definition> 2414408 - Disclosure - Business Combination - Pro Forma Financial Information (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="CashEquivalentsandShortTermInvestments" roleURI="http://www.revance.com/role/CashEquivalentsandShortTermInvestments">
<link:definition> 2115104 - Disclosure - Cash Equivalents and Short-Term Investments </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="CashEquivalentsandShorttermInvestmentsTables" roleURI="http://www.revance.com/role/CashEquivalentsandShorttermInvestmentsTables">
<link:definition> 2316303 - Disclosure - Cash Equivalents and Short-term Investments (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="CashEquivalentsandShorttermInvestmentsDetail" roleURI="http://www.revance.com/role/CashEquivalentsandShorttermInvestmentsDetail">
<link:definition> 2417409 - Disclosure - Cash Equivalents and Short-term Investments (Detail) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="FillerDistributionAgreement" roleURI="http://www.revance.com/role/FillerDistributionAgreement">
<link:definition> 2118105 - Disclosure - Filler Distribution Agreement </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="FillerDistributionAgreementNarrativeDetails" roleURI="http://www.revance.com/role/FillerDistributionAgreementNarrativeDetails">
<link:definition> 2419410 - Disclosure - Filler Distribution Agreement - Narrative (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="IntangibleAssets" roleURI="http://www.revance.com/role/IntangibleAssets">
<link:definition> 2120106 - Disclosure - Intangible Assets </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="IntangibleAssetsTables" roleURI="http://www.revance.com/role/IntangibleAssetsTables">
<link:definition> 2321304 - Disclosure - Intangible Assets (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="IntangibleAssetsIntangibleAssetsandtheRemainingUsefulLivesDetails" roleURI="http://www.revance.com/role/IntangibleAssetsIntangibleAssetsandtheRemainingUsefulLivesDetails">
<link:definition> 2422411 - Disclosure - Intangible Assets - Intangible Assets and the Remaining Useful Lives (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="IntangibleAssetsIntangibleAssetsandtheRemainingUsefulLivesDetails_1" roleURI="http://www.revance.com/role/IntangibleAssetsIntangibleAssetsandtheRemainingUsefulLivesDetails_1">
<link:definition> 2422411 - Disclosure - Intangible Assets - Intangible Assets and the Remaining Useful Lives (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="IntangibleAssetsNarrativeDetails" roleURI="http://www.revance.com/role/IntangibleAssetsNarrativeDetails">
<link:definition> 2423412 - Disclosure - Intangible Assets - Narrative (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="IntangibleAssetsExpectedAmortizationExpensefortheUnamortizedAcquiredIntangibleAssetsDetails" roleURI="http://www.revance.com/role/IntangibleAssetsExpectedAmortizationExpensefortheUnamortizedAcquiredIntangibleAssetsDetails">
<link:definition> 2424413 - Disclosure - Intangible Assets - Expected Amortization Expense for the Unamortized Acquired Intangible Assets (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="Inventories" roleURI="http://www.revance.com/role/Inventories">
<link:definition> 2125107 - Disclosure - Inventories </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="InventoriesDetails" roleURI="http://www.revance.com/role/InventoriesDetails">
<link:definition> 2426414 - Disclosure - Inventories (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="AccrualsandOtherCurrentLiabilities" roleURI="http://www.revance.com/role/AccrualsandOtherCurrentLiabilities">
<link:definition> 2127108 - Disclosure - Accruals and Other Current Liabilities </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="AccrualsandOtherCurrentLiabilitiesTables" roleURI="http://www.revance.com/role/AccrualsandOtherCurrentLiabilitiesTables">
<link:definition> 2328305 - Disclosure - Accruals and Other Current Liabilities (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="AccrualsandOtherCurrentLiabilitiesDetails" roleURI="http://www.revance.com/role/AccrualsandOtherCurrentLiabilitiesDetails">
<link:definition> 2429415 - Disclosure - Accruals and Other Current Liabilities (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="DerivativeLiability" roleURI="http://www.revance.com/role/DerivativeLiability">
<link:definition> 2130109 - Disclosure - Derivative Liability </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="DerivativeLiabilityAdditionalInformationDetail" roleURI="http://www.revance.com/role/DerivativeLiabilityAdditionalInformationDetail">
<link:definition> 2431416 - Disclosure - Derivative Liability - Additional Information (Detail) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="Leases" roleURI="http://www.revance.com/role/Leases">
<link:definition> 2132110 - Disclosure - Leases </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="LeasesTables" roleURI="http://www.revance.com/role/LeasesTables">
<link:definition> 2333306 - Disclosure - Leases (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="LeasesDetails" roleURI="http://www.revance.com/role/LeasesDetails">
<link:definition> 2434417 - Disclosure - Leases (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="LeasesOperatingLeaseCostsDetails" roleURI="http://www.revance.com/role/LeasesOperatingLeaseCostsDetails">
<link:definition> 2435418 - Disclosure - Leases - Operating Lease Costs (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="LeasesOperatingLeaseLiabilityMaturitiesDetails" roleURI="http://www.revance.com/role/LeasesOperatingLeaseLiabilityMaturitiesDetails">
<link:definition> 2436419 - Disclosure - Leases - Operating Lease Liability Maturities (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="LeasesOperatingLeaseLiabilityMaturitiesDetails_1" roleURI="http://www.revance.com/role/LeasesOperatingLeaseLiabilityMaturitiesDetails_1">
<link:definition> 2436419 - Disclosure - Leases - Operating Lease Liability Maturities (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="LeasesSupplementalCashFlowInformationDetails" roleURI="http://www.revance.com/role/LeasesSupplementalCashFlowInformationDetails">
<link:definition> 2437420 - Disclosure - Leases - Supplemental Cash Flow Information (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="ConvertibleSeniorNotes" roleURI="http://www.revance.com/role/ConvertibleSeniorNotes">
<link:definition> 2138111 - Disclosure - Convertible Senior Notes </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="ConvertibleSeniorNotesTables" roleURI="http://www.revance.com/role/ConvertibleSeniorNotesTables">
<link:definition> 2339307 - Disclosure - Convertible Senior Notes (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="ConvertibleSeniorNotesDetails" roleURI="http://www.revance.com/role/ConvertibleSeniorNotesDetails">
<link:definition> 2440421 - Disclosure - Convertible Senior Notes (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="ConvertibleSeniorNotesInterestExpenseDetails" roleURI="http://www.revance.com/role/ConvertibleSeniorNotesInterestExpenseDetails">
<link:definition> 2441422 - Disclosure - Convertible Senior Notes - Interest Expense (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="ConvertibleSeniorNotesCarryingAmountofLiabilityComponentDetails" roleURI="http://www.revance.com/role/ConvertibleSeniorNotesCarryingAmountofLiabilityComponentDetails">
<link:definition> 2442423 - Disclosure - Convertible Senior Notes - Carrying Amount of Liability Component (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="ConvertibleSeniorNotesCappedCallTransactionsDetails" roleURI="http://www.revance.com/role/ConvertibleSeniorNotesCappedCallTransactionsDetails">
<link:definition> 2443424 - Disclosure - Convertible Senior Notes - Capped Call Transactions (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="StockholdersEquityandStockbasedCompensation" roleURI="http://www.revance.com/role/StockholdersEquityandStockbasedCompensation">
<link:definition> 2144112 - Disclosure - Stockholders' Equity and Stock-based Compensation </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="StockholdersEquityandStockbasedCompensationTables" roleURI="http://www.revance.com/role/StockholdersEquityandStockbasedCompensationTables">
<link:definition> 2345308 - Disclosure - Stockholders' Equity and Stock-based Compensation (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="StockholdersEquityandStockbasedCompensationStockOptionPlanAdditionalInformationDetails" roleURI="http://www.revance.com/role/StockholdersEquityandStockbasedCompensationStockOptionPlanAdditionalInformationDetails">
<link:definition> 2446425 - Disclosure - Stockholders' Equity and Stock-based Compensation - Stock Option Plan Additional Information (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="StockholdersEquityandStockbasedCompensationCommonStockEquivalentsExcludedfromtheCalculationofEarningsperShareDetails" roleURI="http://www.revance.com/role/StockholdersEquityandStockbasedCompensationCommonStockEquivalentsExcludedfromtheCalculationofEarningsperShareDetails">
<link:definition> 2447426 - Disclosure - Stockholders' Equity and Stock-based Compensation - Common Stock Equivalents Excluded from the Calculation of Earnings per Share (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="StockholdersEquityandStockbasedCompensationStockOptionPlanScheduleofStockbasedCompensationExpenseDetails" roleURI="http://www.revance.com/role/StockholdersEquityandStockbasedCompensationStockOptionPlanScheduleofStockbasedCompensationExpenseDetails">
<link:definition> 2448427 - Disclosure - Stockholders' Equity and Stock-based Compensation - Stock Option Plan Schedule of Stock-based Compensation Expense (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="FairValueMeasurements" roleURI="http://www.revance.com/role/FairValueMeasurements">
<link:definition> 2149113 - Disclosure - Fair Value Measurements </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="FairValueMeasurementsTables" roleURI="http://www.revance.com/role/FairValueMeasurementsTables">
<link:definition> 2350309 - Disclosure - Fair Value Measurements (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="FairValueMeasurementsScheduleofFairValueofFinancialInstrumentsDetail" roleURI="http://www.revance.com/role/FairValueMeasurementsScheduleofFairValueofFinancialInstrumentsDetail">
<link:definition> 2451428 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Financial Instruments (Detail) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="FairValueMeasurementsSummaryofChangesinFairValueofFinancialInstrumentsDetail" roleURI="http://www.revance.com/role/FairValueMeasurementsSummaryofChangesinFairValueofFinancialInstrumentsDetail">
<link:definition> 2452429 - Disclosure - Fair Value Measurements - Summary of Changes in Fair Value of Financial Instruments (Detail) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="CommitmentsandContingencies" roleURI="http://www.revance.com/role/CommitmentsandContingencies">
<link:definition> 2153114 - Disclosure - Commitments and Contingencies </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="CommitmentsandContingenciesAdditionalInformationDetail" roleURI="http://www.revance.com/role/CommitmentsandContingenciesAdditionalInformationDetail">
<link:definition> 2454430 - Disclosure - Commitments and Contingencies - Additional Information (Detail) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="SegmentInformation" roleURI="http://www.revance.com/role/SegmentInformation">
<link:definition> 2155115 - Disclosure - Segment Information </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="SegmentInformationTables" roleURI="http://www.revance.com/role/SegmentInformationTables">
<link:definition> 2356310 - Disclosure - Segment Information (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="SegmentInformationReconciliationofSegmentRevenuetoConsolidatedRevenueDetails" roleURI="http://www.revance.com/role/SegmentInformationReconciliationofSegmentRevenuetoConsolidatedRevenueDetails">
<link:definition> 2457431 - Disclosure - Segment Information - Reconciliation of Segment Revenue to Consolidated Revenue (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="SegmentInformationReconciliationofSegmentLossfromOperationstoConsolidatedLossfromOperationsDetails" roleURI="http://www.revance.com/role/SegmentInformationReconciliationofSegmentLossfromOperationstoConsolidatedLossfromOperationsDetails">
<link:definition> 2458432 - Disclosure - Segment Information - Reconciliation of Segment Loss from Operations to Consolidated Loss from Operations (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
</xs:appinfo>
</xs:annotation>
<xs:element id="rvnc_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" abstract="false" name="NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="rvnc_CappedCallsPremiumPercentageOverSalePrice" abstract="false" name="CappedCallsPremiumPercentageOverSalePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
<xs:element id="rvnc_TwoThousandAndFourteenEquityIncentivePlanMember" abstract="true" name="TwoThousandAndFourteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rvnc_DerivativeLiabilitySettlementMember" abstract="true" name="DerivativeLiabilitySettlementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rvnc_CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum" abstract="false" name="CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
<xs:element id="rvnc_AdjustmentToAdditionalPaidInCapitalCappedCallTransactions" abstract="false" name="AdjustmentToAdditionalPaidInCapitalCappedCallTransactions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="rvnc_AccruedNonrecurringMilestonePaymentCurrentPortion" abstract="false" name="AccruedNonrecurringMilestonePaymentCurrentPortion" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="rvnc_TwentyTwentySevenNotesMember" abstract="true" name="TwentyTwentySevenNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rvnc_BusinessAcquisitionEquityInterestIssuedNumberOfShares" abstract="false" name="BusinessAcquisitionEquityInterestIssuedNumberOfShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
<xs:element id="rvnc_LesseeOperatingLeaseLeaseNotYetCommencedAmount" abstract="false" name="LesseeOperatingLeaseLeaseNotYetCommencedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="rvnc_SettlementAndTerminationLineItems" abstract="true" name="SettlementAndTerminationLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
<xs:element id="rvnc_StockIssuedDuringPeriodSharesExerciseofWarrants" abstract="false" name="StockIssuedDuringPeriodSharesExerciseofWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
<xs:element id="rvnc_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandAndFourteenEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rvnc_GainLossonDerivativeInstrumentsContractNetPretax" abstract="false" name="GainLossonDerivativeInstrumentsContractNetPretax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="rvnc_CountryPartyNameDomain" abstract="true" name="CountryPartyNameDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rvnc_BioSentinelInc.Member" abstract="true" name="BioSentinelInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rvnc_FollowOnOfferingMember" abstract="true" name="FollowOnOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rvnc_AccruedMilestoneObligations" abstract="false" name="AccruedMilestoneObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="rvnc_DevelopmentServicesMember" abstract="true" name="DevelopmentServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rvnc_WorkingCapitalSurplus" abstract="false" name="WorkingCapitalSurplus" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="rvnc_CollaborativeAgreementContractualPeriod" abstract="false" name="CollaborativeAgreementContractualPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
<xs:element id="rvnc_IncreaseDecreaseinOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseinOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="rvnc_CappedCallsPriceCap" abstract="false" name="CappedCallsPriceCap" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
<xs:element id="rvnc_HintMDMember" abstract="true" name="HintMDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rvnc_DebtConversionTermsTwoMember" abstract="true" name="DebtConversionTermsTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rvnc_AccruedInventoryCurrent" abstract="false" name="AccruedInventoryCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="rvnc_ContingentLicensingRoyaltyRevenue" abstract="false" name="ContingentLicensingRoyaltyRevenue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="rvnc_ProductSegmentMember" abstract="true" name="ProductSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rvnc_TeoxaneAgreementMember" abstract="true" name="TeoxaneAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rvnc_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="rvnc_ServiceSegmentMember" abstract="true" name="ServiceSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rvnc_ValeantPharmaceuticalsInternationalInc.Member" abstract="true" name="ValeantPharmaceuticalsInternationalInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rvnc_CountryPartyNameAxis" abstract="true" name="CountryPartyNameAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
<xs:element id="rvnc_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="rvnc_ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount" abstract="false" name="ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="rvnc_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesAvailableForPurchase" abstract="false" name="BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesAvailableForPurchase" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
<xs:element id="rvnc_AccrualsClinicalTrialsCurrent" abstract="false" name="AccrualsClinicalTrialsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="rvnc_MylanIrelandLimitedMember" abstract="true" name="MylanIrelandLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rvnc_BusinessCombinationConsiderationTransferredEquityInterestsIssuedPreCombinationService" abstract="false" name="BusinessCombinationConsiderationTransferredEquityInterestsIssuedPreCombinationService" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="rvnc_DebtIssuanceCostsGrossEquityComponent" abstract="false" name="DebtIssuanceCostsGrossEquityComponent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="rvnc_DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice" abstract="false" name="DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
<xs:element id="rvnc_StockIssuanceSalesAgreementAuthorizedOfferingPriceMaximum" abstract="false" name="StockIssuanceSalesAgreementAuthorizedOfferingPriceMaximum" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="rvnc_IndemnificationLiabilityRecordedduringPeriod" abstract="false" name="IndemnificationLiabilityRecordedduringPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="rvnc_RevenueRecognitionMilestoneMethodMaximumRevenue" abstract="false" name="RevenueRecognitionMilestoneMethodMaximumRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="rvnc_StockIssuedDuringPeriodSharesRestrictedStockAwardNetofSharesRepurchased" abstract="false" name="StockIssuedDuringPeriodSharesRestrictedStockAwardNetofSharesRepurchased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
<xs:element id="rvnc_MedicisPharmaceuticalCorporationMember" abstract="true" name="MedicisPharmaceuticalCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rvnc_TwoThousandAndFourteenInducementPlanMember" abstract="true" name="TwoThousandAndFourteenInducementPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rvnc_IncreaseDecreaseinOperatingLeaseRightofUseAssets" abstract="false" name="IncreaseDecreaseinOperatingLeaseRightofUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="rvnc_LesseeSupplementalCashFlowInformationTableTextBlock" abstract="false" name="LesseeSupplementalCashFlowInformationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
<xs:element id="rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member" abstract="true" name="ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rvnc_ESPPPurchasesMember" abstract="true" name="ESPPPurchasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rvnc_DebtInstrumentConvertibleTermsOfConversionDomain" abstract="true" name="DebtInstrumentConvertibleTermsOfConversionDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rvnc_CollaborationRevenueMember" abstract="true" name="CollaborationRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rvnc_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfSharesRepurchased" abstract="false" name="StockIssuedDuringPeriodValueRestrictedStockAwardNetOfSharesRepurchased" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="rvnc_CappedCallsNumberOfSharesSubjectToAntidilutionAdjustments" abstract="false" name="CappedCallsNumberOfSharesSubjectToAntidilutionAdjustments" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
<xs:element id="rvnc_DebtInstrumentConvertibleTermsOfConversionAxis" abstract="true" name="DebtInstrumentConvertibleTermsOfConversionAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
<xs:element id="rvnc_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesInEscrow" abstract="false" name="BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesInEscrow" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
<xs:element id="rvnc_DebtIssuanceCostsGrossLiabilityComponent" abstract="false" name="DebtIssuanceCostsGrossLiabilityComponent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="rvnc_CollaborativeAgreementExtendedContractualPeriod" abstract="false" name="CollaborativeAgreementExtendedContractualPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
<xs:element id="rvnc_InternallyDevelopedSoftwareCapitalizedFromStockBasedCompensation" abstract="false" name="InternallyDevelopedSoftwareCapitalizedFromStockBasedCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="rvnc_A2017EquityIncentivePlanHintMDPlanMember" abstract="true" name="A2017EquityIncentivePlanHintMDPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rvnc_AttheMarketOfferingMember" abstract="true" name="AttheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rvnc_BusinessCombinationConsiderationTransferredEquityInterestIssuedAndIssuableEntitySharesIssuedPerAcquireeShare" abstract="false" name="BusinessCombinationConsiderationTransferredEquityInterestIssuedAndIssuableEntitySharesIssuedPerAcquireeShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
<xs:element id="rvnc_ListLaboratoriesMember" abstract="true" name="ListLaboratoriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rvnc_DebtConversionTermsOneMember" abstract="true" name="DebtConversionTermsOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rvnc_FairValueMeasurementInput" abstract="false" name="FairValueMeasurementInput" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
<xs:element id="rvnc_SaleofStockIssuanceCostsCommissionPercentageMaximum" abstract="false" name="SaleofStockIssuanceCostsCommissionPercentageMaximum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
<xs:element id="rvnc_BotulinumToxinResearchAssociatesInc.Member" abstract="true" name="BotulinumToxinResearchAssociatesInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
<xs:element id="rvnc_FairValueMeasurementInputDuration" abstract="false" name="FairValueMeasurementInputDuration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
</xs:schema>

9 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/28/24  Revance Therapeutics, Inc.        10-K       12/31/23  110:12M
 2/28/23  Revance Therapeutics, Inc.        10-K       12/31/22  109:14M
 9/14/22  Revance Therapeutics, Inc.        424B5                  2:545K                                   Donnelley … Solutions/FA
 9/12/22  Revance Therapeutics, Inc.        424B5                  1:519K                                   Donnelley … Solutions/FA
 5/10/22  Revance Therapeutics, Inc.        424B5                  2:504K                                   Donnelley … Solutions/FA
 2/28/22  Revance Therapeutics, Inc.        10-K       12/31/21  106:12M
 2/25/21  Revance Therapeutics, Inc.        10-K       12/31/20  109:12M
 1/29/21  Revance Therapeutics, Inc.        S-8         1/29/21    3:137K
11/27/20  Revance Therapeutics, Inc.        S-3ASR     11/27/20    7:1.1M                                   Donnelley … Solutions/FA

6 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 7/24/20  Revance Therapeutics, Inc.        S-8         7/24/20    4:169K                                   Donnelley … Solutions/FA
 2/14/20  Revance Therapeutics, Inc.        8-K:1,2,3,8 2/11/20   14:1.4M                                   Donnelley … Solutions/FA
 3/04/16  Revance Therapeutics, Inc.        10-K       12/31/15   99:11M
 2/11/14  Revance Therapeutics, Inc.        8-K:5,9     2/11/14    2:49K                                    Donnelley … Solutions/FA
 2/03/14  Revance Therapeutics, Inc.        S-1/A                  5:4.8M                                   Donnelley … Solutions/FA
12/31/13  Revance Therapeutics, Inc.        S-1¶                  30:11M                                    Donnelley … Solutions/FA
↑Top
Filing Submission 0001479290-20-000105   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Wed., May 15, 3:07:59.1pm ET